

Trial Protocol ID	Trial Title	City
3133K1-3000	Bapineuzumab in Apolipoprotein E e4 Non-Carriers With Mild to Moderate Alzheimer Disease	Norwalk
3133K1-3000	Bapineuzumab in Apolipoprotein E e4 Non-Carriers With Mild to Moderate Alzheimer Disease	Greenwich
3133K1-3000	Bapineuzumab in Apolipoprotein E e4 Non-Carriers With Mild to Moderate Alzheimer Disease	Fairfield
3133K1-3001	Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E e4 Carriers	Fairfield
3133K1-3001	Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E e4 Carriers	Norwalk
805003881	Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects	New Haven
2U01AG022376-05A2	The LIFE Study - Lifestyle Interventions and Independence for Elders	New Haven
11935	Continued Safety Monitoring of Solanezumab in Alzheimer's Disease	Fairfield
11935	Continued Safety Monitoring of Solanezumab in Alzheimer's Disease	Hamden
11935	Continued Safety Monitoring of Solanezumab in Alzheimer's Disease	New Haven
11935	Continued Safety Monitoring of Solanezumab in Alzheimer's Disease	Norwalk
B2571010	Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease	New Haven
ADC-039-ADNI2	Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)	New Haven
FMH3-01	Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC	New Haven
GlyT1-01	Research Involving Subjects With Parkinson's Disease, Alzheimer's Disease and Healthy Controls	New Haven
702002301	Amyloid Imaging in Subjects With and At Risk for Alzheimer's Disease: A Positron Emission Tomography (PET) Study.	New Haven,CT



Y 2011-Nov-1 0